The Therapeutic Goods Administration (TGA) has approved Australia’s first ever treatment for nicotine vaping dependence.
Nicorette announced this morning their QuickMist product had been approved by the agenc to be used as a treatment option for nicotine addiction brought about by vaping.
Around 1.7 million people in Australia are estimated vape regularly, with the number having been on the rise since 2018.
READ MORE: Dangerous inmate only cell contact for mushroom killer
However, three in four Aussies said they were planning to stop vaping or cut back in the next three months, in a Quit and Cancer Council survey in May 2024.
Nicorette QuickMist delivers small doses of nicotine to the mouth and is designed to help reduce withdrawal symptoms and reliance on nicotine for users.
Nadine Saraceno, Head of Regulatory Affairs ANZ at Kenvue claimed clinical trials showed highly promising results which prompted the TGA’s decision.
“Our clinical trial demonstrated that Nicorette QuickMist, our fastest acting NRT format, helped reduce nicotine cravings by at least 50 per cent in eight out of 10 nicotine vape users after just one dose,” she said.
READ MORE: Australia Post suspends deliveries to the US after Trump tariffs
“Quitting nicotine vaping can be a challenging journey, particularly without the option of an approved pharmacotherapy.”
Saraceno welcomed the TGA’s decision, believing it would allow treatment options to be more widely available to those in need of support as they try to relieve their nicotine addiction.
“We are proud to offer the first approved option for the relief of nicotine vaping cravings,” she said.
“[It has] the potential to support thousands of Australians in overcoming their dependence on nicotine vaping.”
DOWNLOAD THE 9NEWS APP: Stay across all the latest in breaking news, sport, politics and the weather via our news app and get notifications sent straight to your smartphone. Available on the Apple App Store and Google Play.
